Avenue Therapeutics Completes Last Patient Last Visit In Phase 1b/2a Clinical Trial Of AJ201 For Spinal And Bulbar Muscular Atrophy
Portfolio Pulse from Benzinga Newsdesk
Avenue Therapeutics has completed the last patient visit in its Phase 1b/2a clinical trial of AJ201 for Spinal and Bulbar Muscular Atrophy.
May 16, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avenue Therapeutics has completed the last patient visit in its Phase 1b/2a clinical trial of AJ201 for Spinal and Bulbar Muscular Atrophy.
The completion of the last patient visit in a clinical trial is a significant milestone. It indicates that the trial is progressing as planned and may soon move to the next phase, which is generally positive news for the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100